mitoguazone and Ovarian-Neoplasms

mitoguazone has been researched along with Ovarian-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for mitoguazone and Ovarian-Neoplasms

Article	Year
Phase II study of methyl-glyoxal bis-guanylhydrazone (NSC 3296) in advanced ovarian cancer. American journal of clinical oncology, 1984, Volume: 7, Issue:6 Thirty-nine patients received 600 mg/m2 OF MGBG intravenously every week for the treatment of advanced refractory ovarian cancer. Twenty-seven of these received adequate trials, and only two had partial remissions lasting 3 1/2 and 4 months each. Toxicity was substantial, with severe hematologic toxicity in 26%, diarrhea in 22% (severe in 7%), skin rash in 26% (severe in 7%), and vomiting in 70% (severe in 11%). Fatigue, facial paresthesias, and flushing during drug administration were frequent. It appears that MGBG in this dose and schedule has little activity against advanced ovarian cancer. Topics: Blood; Drug Evaluation; Fatigue; Female; Guanidines; Humans; Mitoguazone; Ovarian Neoplasms; Vomiting	1984
[Histochemical and ultrastructural investigations on the activity of methylglyoxal (bis)-guanylhydrozan (methyl-GAG) on organ cultures of malignant tumors (author's transl)]. Archiv fur Geschwulstforschung, 1977, Volume: 47, Issue:1 Methyl-GAG was tested in organotypic cultures of malignant tumors of human and mice. In 3 cases, a reduction of the activity of two oxydoreductases (lactate dehydrogenase and NADH-diaphorase) after treatment with methyl-GAG was observed whereas in 19 other cultivated tumors no change of enzyme activity was induced by methyl-GAG. Electronmicroscopy revealed only minor structural alterations of tumor cells after application of methyl-GAG as compared with control cultures. Topics: Animals; Breast Neoplasms; Cells, Cultured; Female; Guanidines; Histocytochemistry; Humans; L-Lactate Dehydrogenase; Mammary Neoplasms, Experimental; Melanoma; Mice; Mitoguazone; NADPH Dehydrogenase; Ovarian Neoplasms	1977

Article

Year

Phase II study of methyl-glyoxal bis-guanylhydrazone (NSC 3296) in advanced ovarian cancer.

American journal of clinical oncology, 1984, Volume: 7, Issue:6

Thirty-nine patients received 600 mg/m2 OF MGBG intravenously every week for the treatment of advanced refractory ovarian cancer. Twenty-seven of these received adequate trials, and only two had partial remissions lasting 3 1/2 and 4 months each. Toxicity was substantial, with severe hematologic toxicity in 26%, diarrhea in 22% (severe in 7%), skin rash in 26% (severe in 7%), and vomiting in 70% (severe in 11%). Fatigue, facial paresthesias, and flushing during drug administration were frequent. It appears that MGBG in this dose and schedule has little activity against advanced ovarian cancer.

Topics: Blood; Drug Evaluation; Fatigue; Female; Guanidines; Humans; Mitoguazone; Ovarian Neoplasms; Vomiting

1984

[Histochemical and ultrastructural investigations on the activity of methylglyoxal (bis)-guanylhydrozan (methyl-GAG) on organ cultures of malignant tumors (author's transl)].

Archiv fur Geschwulstforschung, 1977, Volume: 47, Issue:1

Methyl-GAG was tested in organotypic cultures of malignant tumors of human and mice. In 3 cases, a reduction of the activity of two oxydoreductases (lactate dehydrogenase and NADH-diaphorase) after treatment with methyl-GAG was observed whereas in 19 other cultivated tumors no change of enzyme activity was induced by methyl-GAG. Electronmicroscopy revealed only minor structural alterations of tumor cells after application of methyl-GAG as compared with control cultures.

Topics: Animals; Breast Neoplasms; Cells, Cultured; Female; Guanidines; Histocytochemistry; Humans; L-Lactate Dehydrogenase; Mammary Neoplasms, Experimental; Melanoma; Mice; Mitoguazone; NADPH Dehydrogenase; Ovarian Neoplasms

1977